6 MAY 2025TECH OUTLOOKEditorialThe pharmaceutical supply chain is shifting significantly as technology and regulation converge to reshape how drugs are distributed, tracked and packaged. This transformation is evident in controlled substance risk management and pharmaceutical flexographic printing areas.On the distribution side, traditional compliance models can no longer keep pace with rising regulatory scrutiny. Companies now use AI-powered predictive analytics to detect real-time anomalies, flagging supply chain risks before they escalate. Blockchain adds another layer of control, embedding transparency and traceability across the chain to prevent counterfeiting and unauthorized distribution.These tools have become operational necessities. With tighter global rules, pharmaceutical firms invest in real-time monitoring systems that detect diversion risks and enforce chain-of-custody controls. The aim is to reduce risk while gaining a competitive edge through precision and preparedness.Packaging is evolving in parallel. As sustainability goals and labelling requirements grow more demanding, the flexographic printing industry is adapting fast. Digital flexo plates offer higher print quality and less waste, supporting eco-conscious packaging initiatives without compromising performance. Hybrid press technology speeds up production and enables greater flexibility, making it easier to keep up with evolving compliance standards.As a result, the Controlled Substance Distribution Risk Management market is projected to grow at a CAGR of 6.6 percent through 2025, while the Pharmaceutical Flexographic Printing Plates industry is expected to grow at 6.69 percent annually through 2033.The magazine features a thought leadership piece by Haichen Yang, MD, MA, MBA, Vice President of Clinical Research at Amicus Therapeutics, discussing the challenges of placebo-controlled trials in gene therapy and the FDA's growing acceptance of historical data as alternative controls. It also includes insights from Jennifer Perrin, Associate Director of Quality & Compliance at MMS Holdings, on the benefits and risks of outsourcing quality functions in pharma, highlighting the need for qualified consultants and strict regulatory adherence.We also spotlight the stories of pharmaceutical companies delivering solutions that drive innovation. One such company is Quint Company, which has developed precision-engineered flexographic plates, FDA-compliant barcoding and rigorous quality control.In this edition featuring the Best Pharmaceutical Security & DEA Compliance Consulting Firm 2025 and Top Pharmaceutical Flexographic Printing Plates Supplier 2025, we hope you find the right partner to meet your organization's needs.Let us know your thoughts!Shaping the Future of Pharma Risk TECH OUTLOOKMAY - 15 - 2025, Vol 11 - Issue 05 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Editor-in-ChiefStacey SmithEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:VisualizersHenry SmithChris LynnStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comCopyright © 2025 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Disclaimer: * Some of the Insights are based on our interviews with CIOs and CXOs
< Page 5 | Page 7 >